Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD

0.1383  0 (-3.15%)

After market: 0.135 0 (-2.39%)

Fundamental Rating

1

Taking everything into account, AIM scores 1 out of 10 in our fundamental rating. AIM was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of AIM have multiple concerns. While showing a medium growth rate, AIM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AIM has reported negative net income.
In the past year AIM has reported a negative cash flow from operations.
In the past 5 years AIM always reported negative net income.
AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

AIM's Return On Assets of -176.10% is on the low side compared to the rest of the industry. AIM is outperformed by 88.28% of its industry peers.
AIM has a worse Return On Equity (-821.74%) than 83.30% of its industry peers.
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROIC N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Gross Margin of AIM (81.05%) is better than 87.21% of its industry peers.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

1

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIM has been increased compared to 1 year ago.
AIM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AIM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

AIM has an Altman-Z score of -49.84. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
AIM has a Altman-Z score of -49.84. This is amonst the worse of the industry: AIM underperforms 94.32% of its industry peers.
AIM has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.05, AIM is not doing good in the industry: 63.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -49.84
ROIC/WACCN/A
WACC9.44%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.75 indicates that AIM may have some problems paying its short term obligations.
With a Current ratio value of 0.75, AIM is not doing good in the industry: 91.65% of the companies in the same industry are doing better.
A Quick Ratio of 0.75 indicates that AIM may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.75, AIM is doing worse than 91.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AIM have decreased strongly by -12.56% in the last year.
Looking at the last year, AIM shows a decrease in Revenue. The Revenue has decreased by -1.55% in the last year.
The Revenue for AIM have been decreasing by -11.26% on average. This is quite bad
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%

3.2 Future

The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
AIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 217.99% yearly.
EPS Next Y41.93%
EPS Next 2Y17.35%
EPS Next 3Y7.02%
EPS Next 5Y12.45%
Revenue Next Year-7.64%
Revenue Next 2Y306.95%
Revenue Next 3Y262.84%
Revenue Next 5Y217.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.35%
EPS Next 3Y7.02%

More info and screens

0

5. Dividend

5.1 Amount

AIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (2/21/2025, 8:04:00 PM)

After market: 0.135 0 (-2.39%)

0.1383

0 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners7.29%
Inst Owner Change-48.21%
Ins Owners9.54%
Ins Owner Change25%
Market Cap8.82M
Analysts80
Price Target2.81 (1931.81%)
Short Float %1.59%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.26%
Min EPS beat(2)36.63%
Max EPS beat(2)67.89%
EPS beat(4)2
Avg EPS beat(4)7.4%
Min EPS beat(4)-71.62%
Max EPS beat(4)67.89%
EPS beat(8)5
Avg EPS beat(8)6.16%
EPS beat(12)5
Avg EPS beat(12)-7.26%
EPS beat(16)6
Avg EPS beat(16)-9.26%
Revenue beat(2)2
Avg Revenue beat(2)211.11%
Min Revenue beat(2)98.02%
Max Revenue beat(2)324.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.43%
EPS NQ rev (1m)4.17%
EPS NQ rev (3m)-4.55%
EPS NY rev (1m)-2.47%
EPS NY rev (3m)-2.47%
Revenue NQ rev (1m)48.15%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.43
P/FCF N/A
P/OCF N/A
P/B 3.03
P/tB 23.21
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS0.05
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.05%
FCFM N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90%
Cap/Sales 113.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -49.84
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)144.45%
Cap/Depr(5y)112.12%
Cap/Sales(3y)316.9%
Cap/Sales(5y)315.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y41.93%
EPS Next 2Y17.35%
EPS Next 3Y7.02%
EPS Next 5Y12.45%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%
Revenue Next Year-7.64%
Revenue Next 2Y306.95%
Revenue Next 3Y262.84%
Revenue Next 5Y217.99%
EBIT growth 1Y-18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.09%
OCF growth 3YN/A
OCF growth 5YN/A